Stockscreener 앱 받기
15.40
7.47%
1.07
시간 외 거래:
15.40
전일 마감가:
$14.33
열려 있는:
$14.41
하루 거래량:
1.17M
Relative Volume:
0.77
시가총액:
$809.51M
수익:
$59,000
순이익/손실:
$-84.74M
주가수익비율:
-2.645
EPS:
-5.8222
순현금흐름:
$-59.69M
1주 성능:
+17.56%
1개월 성능:
-13.19%
6개월 성능:
-20.00%
1년 성능:
+244.52%
1일 변동 폭
$14.27
$15.50
1주일 범위
$13.00
$15.50
52주 변동 폭
$4.47
$24.27
아발로 테라퓨틱스 Stock (AVTX) Company Profile
명칭
Avalo Therapeutics Inc
전화
410-522-8707
주소
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
15.40 | 767.46M | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
아발로 테라퓨틱스 Stock (AVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | Wolfe Research | Outperform |
| 2026-04-06 | 개시 | Citizens | Mkt Outperform |
| 2026-02-02 | 개시 | Guggenheim | Buy |
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-09-17 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-05 | 개시 | TD Cowen | Buy |
| 2025-08-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-03-25 | 개시 | Jefferies | Buy |
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-28 | 개시 | Piper Sandler | Overweight |
| 2025-02-21 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-10-24 | 개시 | H.C. Wainwright | Neutral |
| 2024-04-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-09-24 | 개시 | RBC Capital Mkts | Outperform |
모두보기
아발로 테라퓨틱스 주식(AVTX)의 최신 뉴스
Avalo Therapeutics advances long‑acting IL‑1β candidate AVTX-010, IND planned for 1H 2027 - TradingView
Avalo Therapeutics plans IND submission for AVTX-010 in H1 2027 - Investing.com Canada
Avalo develops longer-lasting antibody to enable less frequent dosing - Stock Titan
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody - GlobeNewswire
Avalo Therapeutics stock soars after positive LOTUS trial results - MSN
AVTX Initiates Coverage On B of A Securities -- Rating Set to Bu - GuruFocus
Avalo Therapeutics amends preferred stock terms and executive agreements - Investing.com
Avalo Therapeutics Expands Ownership Limits, Updates Executive Contracts - TipRanks
Avalo Therapeutics (AVTX) CSO logs 588-share tax-withholding transaction - Stock Titan
Avalo Therapeutics (AVTX) CLO logs tax-withholding of 1,081 shares on Form 4 - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) CFO logs tax-withholding share move - Stock Titan
[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) creates Series C-1 preferred and enhances executive change-in-control pay - Stock Titan
BofA Securities Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $35 - Moomoo
This Keurig Dr Pepper Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
BofA initiates Avalo Therapeutics stock with buy rating on HS drug - Investing.com Nigeria
FMR LLC's Strategic Acquisition of Avalo Therapeutics Inc Shares - GuruFocus
AVALO THERAPEUTICS INC (AVTX) Stock Chart - ChartMill
Avalo Therapeutics: Sell-Off Could Continue If Overall Market Deteriorates Further - Seeking Alpha
Avalo Therapeutics elects directors, approves stock plan and auditor at annual meeting - Investing.com UK
Avalo Therapeutics (AVTX) holders approve ESPP, elect 7 directors and ratify Ernst & Young - Stock Titan
Avalo Therapeutics prices $375 million stock offering By Investing.com - Investing.com Nigeria
FMR LLC amendment shows 3.19M shares in Avalo Therapeutics (AVTX) - Stock Titan
Deep Track Capital, LP Acquires Significant Stake in Avalo Thera - GuruFocus
Deep Track Capital, LP Acquires Significant Stake in Avalo Therapeutics Inc - GuruFocus
Director at Avalo Therapeutics (AVTX) granted 20,100 stock options - Stock Titan
Avalo Therapeutics (AVTX) director receives grant of 20,100 stock options at $13.96 - Stock Titan
Avalo Therapeutics (AVTX) director receives 20,100 stock options at $13.96 strike - Stock Titan
Avalo Therapeutics (AVTX) director receives stock options for 20,100 shares - Stock Titan
Avalo Therapeutics (AVTX) director awarded 29,500 options at $13.96 strike - Stock Titan
Avalo Therapeutics (AVTX) director granted 20,100 stock options at $13.96 strike - Stock Titan
Avalo Therapeutics (AVTX) Edges Higher as Stock Tests Key Near-Term ResistanceBPI Bear Correction - newsline.com
AVTX: Broker-listed notice for proposed sales of 43,?33 shares (06/02/2026) - Stock Titan
Avalo Therapeutics (AVTX) CMO sells shares under 10b5-1 plan - Stock Titan
AVTX Q1 2026 Earnings: Narrower Loss Lifts Investor Sentiment Amid Continued Pre-Revenue StageOperating Margin Analysis - newsline.com
Deep Track holds 5.81% of Avalo Therapeutics (AVTX) in Schedule 13G filing - Stock Titan
AVTX News | AVALO THERAPEUTICS INC (NASDAQ:AVTX) - ChartMill
Avalo Therapeutics (AVTX) Stock Price, Quote, Charts & News - Invezz
Point72 (AVTX) reports 2.71M-share, 5.2% position in Avalo Therapeutics - Stock Titan
Avalo Therapeutics (AVTX) CSO granted 34,200 performance stock units vesting in 2028 - Stock Titan
Avalo Therapeutics (AVTX) CFO receives 39,900 PSU-linked shares in equity award - Stock Titan
Avalo Therapeutics (AVTX) CLO granted 24,300 performance-based common shares - Stock Titan
Avalo Therapeutics (AVTX) CMO receives 43,500-share performance award - Stock Titan
Performance stock units expand Avalo (NASDAQ: AVTX) CEO’s stake - Stock Titan
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Avalo Therapeutics (AVTX) Holds Steady Near Key Support LevelsRetail Driven Moves - newsline.com
AVTX Q1 2026 Earnings: Narrower-Than-Expected Loss Marks a Slight Positive SurpriseOne-Time Loss Impact - newsline.com
Avalo Therapeutics (AVTX) CMO exercises options and sells 3,000 shares under plan - Stock Titan
Avalo Therapeutics (AVTX) price target increased by 18.49% to 47.94 - MSN
UBS Group AG Has $8.68 Million Stock Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty - TipRanks
아발로 테라퓨틱스 (AVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아발로 테라퓨틱스 주식 (AVTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Doyle Mittie | Chief Medical Officer |
May 28 '26 |
Option Exercise |
8.04 |
679 |
5,459 |
47,801 |
| Doyle Mittie | Chief Medical Officer |
May 28 '26 |
Sale |
16.00 |
679 |
10,864 |
47,122 |
| Doyle Mittie | Chief Medical Officer |
May 15 '26 |
Option Exercise |
12.65 |
3,000 |
37,950 |
6,622 |
| Doyle Mittie | Chief Medical Officer |
May 15 '26 |
Sale |
18.76 |
3,000 |
56,280 |
3,622 |
| Sullivan Christopher Ryan | Chief Financial Officer |
May 07 '26 |
Option Exercise |
9.88 |
18,606 |
183,827 |
19,029 |
| Sullivan Christopher Ryan | Chief Financial Officer |
May 07 '26 |
Sale |
24.12 |
18,606 |
448,818 |
423 |
2.60%
0.94%
자본화:
|
볼륨(24시간):